COMMITMENTS AND CONTINGENCIES (Details Narrative) $ in Thousands													1 Months Ended					3 Months Ended							9 Months Ended		12 Months Ended
	Jul. 17, 2024 USD ($)	Jul. 01, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jun. 03, 2024 shares	Feb. 29, 2024 USD ($)	Jan. 26, 2024 USD ($) shares	Aug. 22, 2023 USD ($)	Oct. 06, 2022 USD ($)	Oct. 03, 2022	Mar. 31, 2021 USD ($)	Apr. 28, 2019 USD ($)	Jan. 04, 2018 USD ($) shares	Dec. 31, 2024 USD ($)	Sep. 30, 2024 USD ($)	Jul. 31, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2012	Sep. 30, 2024 USD ($) shares	Jun. 30, 2024 USD ($) shares		Mar. 31, 2024 USD ($) shares		Jun. 30, 2023 USD ($) shares		Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2024 ILS (₪)	Dec. 11, 2022 USD ($)	Dec. 11, 2022 ILS (₪)	Jun. 10, 2021 USD ($)
Net sales royalty percenatge																									3.00%
Gross proceeds from cash fee percentage									7.00%
Gross proceeds from management fee percentage									1.00%
Stock issued during period, value, new issues																			$ 2,022	[1]	$ 2,397	[2]	$ 6,558
Litigation settlement amount						$ 2,154
Settlement agreement liability																											$ 2,211
Insurance recoverable																											1,335
Settlement amount recovery																											1,100
Legal expense																											235
Non operating loss on legal settlement																											$ 1,111
New funds not raise																									$ 5,104	$ 6,558
Joseph Mona [Member]
Purchase price of plaintiffs							$ 485			$ 485
Chief Executive Officer [Member]
Contingent cash bonus	$ 149		$ 149											$ 149		$ 149		$ 149	149						149
Percentage of contingent cash bonus	50.00%													50.00%		50.00%
Chief Executive Officer [Member] | Forecast [Member]
New funds not raise													$ 10,000
Other Executives [Member]
Contingent cash bonus														$ 61				61							61			₪ 230,736
New funds not raise	$ 3,000				$ 3,000
Chief Financial Officer and Chief Technology Officer [Member]
Contingent cash bonus														61				$ 61							61
Device [Member]
Royalties percentage								3.00%
Integrated Product [Member]
Royalties percentage								1.50%
Common Stock [Member]
Stock issued during period, value, new issues																			$ 16	[1]	$ 17	[2]	$ 35
Number of share issued | shares																			1,566,669	[1]	1,685,682	[2]	3,576,689	[2]
Cardio Sert [Member]
Aggregate amount															$ 530
At-the-Market Offering Agreement [Member] | Common Stock [Member]
Sale of Stock, Consideration Received on Transaction		$ 4,820
Percentage of placement fee		3.00%
Number of share issued | shares																		685,800
Securities Purchase Agreement [Member]
Purchase price of plaintiffs																									$ 6,750
Securities Purchase Agreement [Member] | Common Stock [Member]
Number of share issued | shares				1,566,669
Litigation Settlement [Member]
Payment for litigation settlement						$ 1,100															$ 1,100
Restricted common shares issued for legal settlement | shares						1,005,965
Insurance recovery amount																					$ 1,335
Litigation Settlement [Member] | Common Stock [Member]
Number of share issued | shares																					1,005,965				1,005,965
Minimum [Member] | Chief Executive Officer [Member]
New funds not raise			$ 3,000											6,000		$ 3,000
Maximum [Member] | Chief Executive Officer [Member]
Contingent cash bonus					$ 298
Israeli Innovation Authority [Member]
Grants receivable														378				$ 378							$ 378				$ 83	₪ 300,000
Additional grant receivable														447				447							$ 447			₪ 1,620,000
Israeli Innovation Authority [Member] | Minimum [Member]
Net sales royalty percenatge																									3.00%
Israeli Innovation Authority [Member] | Maximum [Member]
Net sales royalty percenatge																									5.00%
Israeli Innovation Authority [Member] | CardioSert Ltd [Member]
Repayment of government grants												$ 530
Israeli Innovation Authority [Member] | Nitiloop [Member]
Repayment of government grants								$ 925
Ministry of Economy [Member]
Grants receivable														$ 50				$ 50							$ 50
Technion Research and Development Foundation Limited [Member] | Minimum [Member]
Net sales royalty percenatge																	1.50%
Technion Research and Development Foundation Limited [Member] | Maximum [Member]
Net sales royalty percenatge																	3.00%
CardioSert Ltd [Member] | Technology [Member]
Payment to acquire intangible assets												$ 300
Number of common shares issued for acquisition | shares												6,738
Number of common shares issued for acquisition, value												$ 74
H.C. Wainwright & Co. LLC [Member]
Warrant issued, descriptions									The Company has also agreed to issue to Wainwright or its designees preferred investment options upon the closing of such offerings, equal to five (5.0%) percent of the aggregate number of such shares of common stock in such offerings, including upon exercise for cash of any warrants issued to investors in such offering.
H.C. Wainwright & Co. LLC [Member] | At-the-Market Offering Agreement [Member]
Offering costs																															$ 10,000
Stock issued during period, value, new issues								$ 8,000
Alliance Investment Management, Ltd. [Member]
Litigation settlement											$ 468
2013 Through June 30, 2024 [Member] | Israeli Innovation Authority [Member]
Revenue grants received																									$ 1,878

[1] Net of issuance costs in the amount of approximately $328. See also Note 4B.

[2] Net of issuance costs in the amount of approximately $333. See Note 4A.